Tag Archives: TROV

TrovaGene (TROV) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on TrovaGene (TROV – Research Report) yesterday and set a price target of $6.00. The company’s shares closed last Monday at $1.38, close to its 52-week low of $1.21. According to

TrovaGene (TROV) Receives a Buy from Noble Financial

Noble Financial analyst Ahu Demir maintained a Buy rating on TrovaGene (TROV – Research Report) yesterday and set a price target of $23.00. The company’s shares closed last Monday at $1.34, close to its 52-week low of $1.21. According to

Noble Financial Sticks to Their Buy Rating for TrovaGene (TROV)

In a report released yesterday, Ahu Demir from Noble Financial reiterated a Buy rating on TrovaGene (TROV – Research Report), with a price target of $23. The company’s shares closed last Monday at $1.92, close to its 52-week low of

Wednesday’s Midday Stock Update: Samsung Electronics (SSNLF), Cree (CREE), Akorn (AKRX), TrovaGene (TROV), Can-Fite BioPharma (CANF)

So far Wednesday, August 21, NASDAQ is up 0.22% and the S&P is up 0.1%. Here are this morning’s most active stocks: Samsung Electronics (SSNLF – Research Report), Cree (CREE – Research Report), Akorn (AKRX – Research Report), TrovaGene (TROV

Thursday’s Highlights at Noon: American Green Inc (ERBB), Samsung Electronics (SSNLF), ImmunoCellular Therapeutics (IMUC), Fuelcell Energy (FCEL), TrovaGene (TROV)

So far Thursday, August 15, NASDAQ is down -0.83% and the S&P is down -0.02%. Here are this morning’s most active stocks: American Green Inc (ERBB – Research Report), Samsung Electronics (SSNLF – Research Report), ImmunoCellular Therapeutics (IMUC – Research

Maxim Group Keeps Their Buy Rating on TrovaGene (TROV)

Maxim Group analyst Jason McCarthy maintained a Buy rating on TrovaGene (TROV – Research Report) yesterday and set a price target of $6. The company’s shares closed yesterday at $1.63, close to its 52-week low of $1.60. McCarthy noted: “Trovagene